MECHANISM OF ACTION OF TYROSINE KINASE INHIBITORS
Keywords:
Keywords: tyrosine kinase inhibitors, molecular mechanisms, targeted therapy, cancer, signal transduction, drug resistance.Abstract
This thesis explores the molecular mechanisms of action of tyrosine kinase inhibitors (TKIs) and their role in targeted cancer therapy. It examines their effects on intracellular signaling pathways, including RAS–RAF–MEK–ERK, PI3K–AKT–mTOR, and JAK–STAT, and their therapeutic applications in various malignancies. Particular attention is given to the mechanisms of drug resistance, including kinase-domain mutations and activation of alternative signaling pathways. The review also highlights recent advances in the development of selective inhibitors and combination therapies to improve treatment efficacy and support personalized cancer management.
References
1. Kumar R, Goel H, Solanki R, et al. Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy. Medicine in Drug Discovery. 2024;23:100195. doi:10.1016/j.medidd.2024.100195.
2. Levitzki A, Gazit A. Tyrosine kinase inhibition: An approach to drug development. Science. 1995;267(5205):1782–1788. doi:10.1126/science.7892601.
3. Busse D, Yakes FM, Lenferink AE, Arteaga CL. Tyrosine kinase inhibitors: Rationale, mechanisms of action, and implications for drug resistance. Seminars in Oncology. 2001;28(5 Suppl 16):47–55. doi:10.1016/S0093-7754(01)90282-9.
4. Lahmouad M, Rachid Z, Bellemrrabet R, et al. Mechanisms and signaling pathways of tyrosine kinase inhibitor resistance in chronic myeloid leukemia: A comprehensive review. Leukemia Research Reports. 2025;24:100533. doi:10.1016/j.lrr.2025.100533.
5. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105(7):2640–2653. doi:10.1182/blood-2004-08-3097.
6. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nature Reviews Cancer. 2009;9(1):28–39. doi:10.1038/nrc2559.